Further, mutations in CTNNB1, previously associated with a non-polypous pathway of tumour progression [64], are prevalent in MLH1-deficient but not MSH2- or MSH6-deficient LS CRCs [63]. This evidence concerns the gene MLH1 and neoplasm.